Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kiora Pharmaceuticals Pty Ltd. is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. The prosecution of its patent applications is handled by 1 distinct examiner, reflecting a narrow scope of current activity at the patent office. This concentration suggests that the company is currently focused on a specific pharmaceutical innovation rather than a broad portfolio of diverse technologies.
The data shows that the portfolio is being processed within 1 distinct art unit. FETTEROLF, BRANDON J is the busiest examiner assigned to the company, with 1 pending office action currently under review. Because the company only has 1 pending office action in total, this examiner is responsible for the entirety of the active prosecution workload. This focus within the Biotechnology & Pharmaceuticals sector highlights the importance of this specific examiner's evaluation.
Practitioners should recognize that having 1 distinct examiner and 1 distinct art unit simplifies the management of the portfolio. The lack of multiple pending actions reduces the complexity of the prosecution strategy, as all current efforts are directed toward the 1 pending office action managed by FETTEROLF, BRANDON J. This allows for a specific response strategy tailored to the examiner's feedback in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18647758 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | FETTEROLF, BRANDON J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18647758 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647758 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | FETTEROLF, BRANDON J | 1626 | §102§103Other | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKiora Pharmaceuticals Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brandon J Fetterolf has the most, with 1 of Kiora Pharmaceuticals Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
